Christopher Rowe

Dr. Christopher Rowe


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
CRChristopher Rowe
Christopher Rowe
JPJonathan Paul
Jonathan Paul
CGCraig Gedye
Craig Gedye
JTJorge M Tolosa
Jorge M Tolosa
CBCino Bendinelli
Cino Bendinelli
RSRoger Smith
Roger Smith
Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.

1 January 2018 in The American Journal of Pathology
Verified
Journal Article
Closed access
SFSam Faulkner
Sam Faulkner
PJPhilip Jobling
Philip Jobling
CRChristopher Rowe
Christopher Rowe
Sonia M Rodrigues OliveiraSonia M Rodrigues Oliveira
Sonia M Rodrigues Oliveira
SRSeverine Roselli
Severine Roselli
Hubert HondermarckHubert Hondermarck
Hubert Hondermarck

30 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CRChristopher Rowe
Christopher Rowe
TDTony Dill
Tony Dill
NGNathan Griffin
Nathan Griffin
PJPhil Jobling
Phil Jobling
SFSam Faulkner
Sam Faulkner
Hubert HondermarckHubert Hondermarck
Hubert Hondermarck
Nerves are emerging regulators of cancer progression and in several malignancies innervation of the tumour microenvironment is associated with tumour aggressiveness. However, the innervation of thyroid cancer is unclear. Here, we investigated the presence of nerves in thyroid cancers and the potential associations with clinicopathological parameters. Nerves were detected by immunohistochemistry using the pan-neuronal marker PGP9.5 in whole-slide sections of papillary thyroid cancer (PTC) (n = 75), compared to follicular thyroid cancer (FTC) (n = 13), and benign thyroid tissues (n = 26). Nerves were detected in most normal thyroid tissues and thyroid cancers, but nerve density was increased in PTC (12 nerves/cm2 [IQR 7–21]) compared to benign thyroid (6 nerves/cm2 [IQR: 3–10]) (p = 0.001). In contrast, no increase in nerve density was observed in FTC. In multivariate analysis, nerve density correlated positively with extrathyroidal invasion (p < 0.001), and inversely with tumour size (p < 0.001). The majority of nerves were adrenergic, although cholinergic and peptidergic innervation was detected. Perineural invasion was present in 35% of PTC, and was independently associated with extrathyroidal invasion (p = 0.008). This is the first report of infiltration of nerves into the tumour microenvironment of thyroid cancer and its association with tumour aggressiveness. The role of nerves in thyroid cancer pathogenesis should be further investigated.

10 September 2019 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
AMA. L. Marlow
A. L. Marlow
CRChristopher Rowe
Christopher Rowe
DAD. Anderson
D. Anderson
Katie WynneKatie Wynne
Katie Wynne
BKB. R. King
B. R. King
CSCarmel Elizabeth Smart
Carmel Elizabeth Smart

1 November 2018 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
CRChristopher Rowe
Christopher Rowe
SASam Arthurs
Sam Arthurs
COChristine J. O’nEill
Christine J. O’nEill
JHJacqueline Hawthorne
Jacqueline Hawthorne
RCRosemary Carroll
Rosemary Carroll
CBCino Bendinelli
Cino Bendinelli

15 November 2018 in Diabetic Medicine
Verified
Journal Article
Closed access
PDF file
CRChristopher Rowe
Christopher Rowe
EPE. Putt
E. Putt
OBO. Brentnall
O. Brentnall
AGA. Gebuehr
A. Gebuehr
JAJ. Allabyrne
J. Allabyrne
Katie WynneKatie Wynne
Katie Wynne